UCB
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 5 | 4 | live | 3 | 1 |
| Research labs and data | No eligible company disclosure identified | No eligible company disclosure identified | 0 | 4 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
AI in drug discovery at UCB scores 5 out of 10 for priority and 4 for delivery, at the live stage. UCB says its collaborations with Schrödinger bring modelling and computational design into discovery, and on 1 May 2026 it acquired the IMIDomics Patient Insight Business, gaining a curated human immunology dataset and a platform that applies machine learning and AI to find new drug targets. Three AI in drug discovery commitments were made public in the last 12 months: the IMIDomics deal, the DARC in-silico antibody design collaboration with the University of Southampton, and a new Barcelona R&D Hub building an in-house AI precision medicine platform; one, the XtalFold biologics AI licence from XtalPi's Ailux Biologics, was made public in the year before. For research labs and data, no eligible company disclosure was identified; the only related commitment is the Arkelia R&D building at Braine-l'Alleud, announced in February 2025 and planned with automated systems. On 6 October 2026 UCB had 1 R&D role open in AI in drug discovery and 4 in research labs and data, including a Head of Scientific Computing & Technology and two Data Foundations Leads.
AI in drug discovery
What the company says: Priority 5
UCB has acquired the Patient Insight Business of IMIDomics ... which applies advanced biostatistics, machine learning, and AI to uncover new therapeutic targets, responder biomarkers
UCB announces acquisition of IMIDomics' Patient Insight Business, 1 May 2026
Patient Insight Business enhances UCB’s ability to identify novel drug targets, discover responder biomarkers, and design molecularly informed patient stratification approaches
UCB announces acquisition of IMIDomics' Patient Insight Business, 1 May 2026
On 1 May 2026, the Group acquired the Patient Insight Business of IMIDomics. The acquisition provides UCB with direct access to one of the most advanced, deeply curated human datasets in immunology
UCB 2026 Half-Year Financial Report, 30 Jul 2026, p. 29
Cutting-edge digital technologies, including combinatorial biology, rational drug design and artificial intelligence, allow us to identify promising therapeutic candidates with greater speed and precision.
UCB Integrated Annual Report 2025, Feb 2026, p. 15
Today, we are investing in the next wave of scientific breakthroughs, combining advances in combinatorial biology, digital antibody engineering and precision data science.
UCB Integrated Annual Report 2025, Feb 2026, p. 11
represents a significant step in our strategy to build the most robust, human data–driven platform in immune mediated diseases
UCB announces acquisition of IMIDomics' Patient Insight Business, 1 May 2026
In 2025, we confirmed the results of our 2023 double materiality assessment, identifying the highest-priority areas that are deeply connected to our purpose and where we can have the biggest societal impact.
UCB Integrated Annual Report 2025, Feb 2026, p. 15
For more details on our work across these focus areas, please see the Sustainability Statement on pages 47.
UCB Integrated Annual Report 2025, Feb 2026, p. 18
What it shows running: Delivery 4, live
Our collaborations with Schrödinger are also integrating advanced modeling and computational design, to accelerate discovery and enhance data quality across key R&D pillars such as multi-specific medicines and digital antibody engineering.
UCB Integrated Annual Report 2025, 26 Feb 2026, p. 19
On 1 May 2026, the Group acquired the Patient Insight Business of IMIDomics. The acquisition provides UCB with direct access to one of the most advanced, deeply curated human datasets in immunology
UCB 2026 Half-Year Financial Report, 30 Jul 2026, p. 29
In January 2025, UCB entered into a license agreement on XtalFold™, a biologics AI platform developed by Ailux Biologics, a division of XtalPi. UCB will leverage XtalFold™ for the discovery and engineering of biologics.
UCB Integrated Annual Report 2025, Feb 2026, p. 180
artificial intelligence, allow us to identify promising therapeutic candidates with greater speed and precision
UCB Integrated Annual Report 2025, 26 Feb 2026, p. 15
This forward-thinking initiative is focused on developing an end-to-end platform for the in-silico design of therapeutic antibodies
The new three-year initiative will combine UCB's expertise in digital antibody development
Our partnership with Stanford University is exploring digital phenotyping and computational discovery of HS mechanisms
UCB Integrated Annual Report 2025, Feb 2026, p. 22
allow us to identify promising therapeutic candidates with greater speed and precision
UCB Integrated Annual Report 2025, Feb 2026, p. 15
Commitments made public in the last 12 months: 3
- Barcelona R&D Hub and in-house AI precision medicine platform: Job posting states UCB has a new Barcelona R&D Hub building an AI-powered precision medicine platform for discovery. New, in build, 22 Sep 2026. Published by: company.
- IMIDomics: equity investment and acquisition of the Patient Insight Business: Acquired IMIDomics Patient Insight Business, including its ML and AI analytic platform for target discovery, staff and labs. New, announced, 1 May 2026. Published by: joint release.
- DARC: Digital Antibody Research Collaboration with the University of Southampton: Three-year academic collaboration to develop an end-to-end in-silico antibody design platform; announced. New, announced, 27 Apr 2026. Published by: joint release.
Commitments made public in the year before: 1
- Ailux Biologics (XtalPi) XtalFold biologics AI platform licence: Non-exclusive licence to use Ailux XtalFold AI structure platform for biologics discovery and engineering. New, announced, 9 Jan 2025. Published by: joint release.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 1
- Lead Full-Stack AI Product Engineer - Barcelona (SP), N/A, N/A, Spain
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Asked for as experience: Python, R.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Research labs and data
No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 1
- Arkelia R&D facility, Braine-l'Alleud campus: Construction start of a research and early-development building (about 170 staff) that the release says will have cutting-edge automated systems; fully operational by mid-2028. New, in build, 10 Feb 2025. Published by: company.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 4
- Head of Scientific Computing & Technology, Anderlecht, Brussels, Belgium
- Data Foundations Lead in R&D, Boston, Massachusetts, United States
- Data Foundations Lead, Slough, Berkshire, United Kingdom
- Lead Full-Stack AI Product Engineer - Barcelona (SP), N/A, N/A, Spain
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Asked for as experience: Python, R.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Two questions to investigate (Ortent's interpretation)
- Research computing, research data standards and development lab systems sit in different UCB units. What is each unit's remit for research labs as against development labs, and who decides on lab automation and lab informatics purchases for the Arkelia building, with what role for Procurement?
- UCB's AI discovery work mixes an external licence, Schrödinger collaborations, an academic partnership, an acquired platform and an in-house platform at the Barcelona hub, and the sources do not say whether the Barcelona platform is the IMIDomics platform. Who decides whether to license or build an AI discovery tool, which route does a licence take, and who owns and funds the Barcelona platform?
Coverage limits
The web search budget was capped, and several planned searches were not run, including lab data consortium, lab automation academic and UCB Ventures searches. Results presentations and call transcripts for the year before could not be found on UCB's site, and Business Wire and GlobeNewswire were not fetched. UCB's venture site and its online annual report returned security checkpoint pages and Fierce Biotech blocked access, so the venture portfolio was read only in summary and the annual report from PDFs. These gaps fall most on research labs and data and on the year before, so the finding of no eligible research labs and data disclosure rests on partial searches.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call